After promising to sell off 7% of its business back in November, Charles River Laboratories has delivered. | After promising to sell off 7% of its business back in November, Charles River Laboratories ...

Charles River to sell CDMO, Cell Solutions, and European assets, raise 2026 earnings outlook as shares trade near 52-week lows.

Charles River Laboratories agreed to sell certain drug discovery assets to IQVIA for about $145 million and to divest its contract development and manufacturing and cell solutions businesses to GI ...

IQVIA Holdings Inc. ("IQVIA") (NYSE: IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has ...

Charles River Laboratories International (NYSE:CRL) reported fourth-quarter and full-year 2025 results that landed at the high end of management’s November outlook, while outlining 2026 guidance that ...

Charles River Laboratories (CRL) reported $994.23 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 0.8%. EPS of $2.39 for the same period compares to $2 ...

Charles River Laboratories International Inc. (CRL) on Wednesday reported a loss of $276.6 million in its fourth quarter.

Charles River Laboratories International, Inc. (NYSE:CRL) is one of the 12 best mid cap AI stocks to buy according to hedge funds. Charles Rhyee, an analyst at TD Cowen, increased the firm’s price ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Wilmington company is ...

Charles River Laboratories is continuing its run of layoffs by announcing the closure of its cell therapy contract development and manufacturing organization (CDMO) site in Hanover, Maryland that will ...

(RTTNews) - Charles River Laboratories International Inc. (CRL) unveiled a series of strategic moves at the J.P. Morgan 44th Annual Healthcare Conference, including two planned acquisitions, a key ...

Charles River Laboratories (CRL) exercised its option to acquire the remaining 79% equity stake that it does not already own of PathoQuest, a Paris, France-based provider of next generation sequencing ...